Shoma Yamamoto

Shoma Yamamoto

Auto-generated profile, based on publicly available information

Shoma Yamamoto

Department of Urology, Graduate School of Medicine Osaka Metropolitan University Osaka Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Open access
SYShoma Yamamoto
Shoma Yamamoto
MKMinoru Kato
Minoru Kato
YTYuji Takeyama
Yuji Takeyama
NYNao Yukimatsu
Nao Yukimatsu
YHYukiyoshi Hirayama
Yukiyoshi Hirayama
JUJunji Uchida
Junji Uchida
Recently, switch maintenance with avelumab has been approved for the treatment of advanced or metastatic urothelial carcinoma (UC), with no progression after four to six cycles of first-line platinum-based chemotherapy. However, the optimal number of cycles of platinum-based chemotherapy has not been determined. To analyze the clinical characteristics of patients with advanced UC who were treated with platinum-based chemotherapy and investigate the association between the number of cycles of the treatment and the patients' overall survival. A total of 124 patients with advanced UC who were treated with first-line platinum-based chemotherapy at Osaka City University Hospital between April 2009 and January 2020 were retrospectively reviewed. Of the 124 patients, clinical information regarding overall survival was available for 115 patients. The median age was 72 years (range, 43-95 years). Only 59 patients (51.3 %) were treated with gemcitabine and cisplatin, and 52 patients (45.2 %) were treated with gemcitabine and carboplatin. The median number of cycles was three (1-8), and the percentage of patients who discontinued chemotherapy due to progressive disease was 80.3%, 64.0%, and 86.4% in those receiving one to three, four, and five or more cycles, respectively. Moreover, no difference in overall survival was observed between patients who received four cycles and those who received five or more cycles at both univariate and multivariate levels. The present study shows that five or more cycles of first-line platinum-based chemotherapy did not prolong overall survival compared with four cycles, suggesting that four cycles of chemotherapy might be sufficient, considering the new treatment strategy involving switch maintenance with avelumab.

17 April 2023 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
SYShoma Yamamoto
Shoma Yamamoto
MKMinoru Kato
Minoru Kato
YTYuji Takeyama
Yuji Takeyama
YAYukari Azuma
Yukari Azuma
NYNao Yukimatsu
Nao Yukimatsu
JUJunji Uchida
Junji Uchida
Background: Radiotherapy (RT) has recently been highlighted as a partner of immune checkpoint inhibitors. The advantages of RT include activation of lymphocytes while it potentially recruits immunosuppressive cells, such as myeloid-derived suppressor cells (MDSCs). This study aimed to investigate the mechanism of overcoming treatment resistance in immunologically cold tumours by combining RT and MDSC-targeted therapy. Methods: The abscopal effects of irradiation were evaluated using MB49 and cisplatin-resistant MB49R mouse bladder cancer cells, with a focus on the frequency of immune cells and programmed cell death-ligand 1 (PD-L1) expression in a xenograft model. Results: MB49R was immunologically cold compared to parental MB49 as indicated by the fewer CD8+ T cells and lower PD-L1 expression. Polymorphonuclear MDSCs increased in both MB49 and MB49R abscopal tumours, whereas the infiltration of CD8+ T cells increased only in MB49 but not in MB49R tumours. Interestingly, PD-L1 expression was not elevated in abscopal tumours. Finally, blocking MDSC in combination with RT remarkably reduced the growth of both MB49 and MB49R abscopal tumours regardless of the changes in the frequency of infiltrating CD8+ T cells. Conclusions: The combination of RT and MDSC-targeted therapy could overcome treatment resistance in immunologically cold tumours.

15 November 2023 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
TMTaisuke Matsue
Taisuke Matsue
MKMinoru Kato
Minoru Kato
YKYuki Kosugi
Yuki Kosugi
KIKota Ishizaki
Kota Ishizaki
HMHiroo Masuda
Hiroo Masuda
JUJunji Uchida
Junji Uchida
Adjuvant nivolumab prolonged disease-free survival compared with placebo in patients at high risk of recurrence following radical cystectomy or radical nephroureterectomy in the CheckMate 274 trial. However, the ideal eligibility criteria for adjuvant therapy in real-world clinical practice remain controversial. We retrospectively analyzed clinical data of 409 patients who underwent radical cystectomy (n = 252) or radical nephroureterectomy (n = 157) and validated the risk of recurrence based on the classification used in the CheckMate 274 trial. We also investigated the impact of perioperative chemotherapy, lymph node dissection and pathological factors on prognosis. The median follow-up time was 37.5 and 32.1 months in bladder cancer and upper tract urothelial carcinoma, respectively. Among the high-risk patients based on CheckMate 274 trial, disease-free survival was considerably shorter for bladder cancer and upper tract urothelial carcinoma patients than for low-risk patients (hazard ratios: 4.132 and 7.101, respectively). The prevalence of adjuvant chemotherapy in high-risk patients was low (24 and 38% for bladder cancer and upper tract urothelial carcinoma, respectively). The extent of lymph node dissection in bladder cancer and presence of lymph node dissection in upper tract urothelial carcinoma did not affect prognosis. Cox proportional multivariate analysis revealed CheckMate 274-high-risk as a poor prognostic factor in bladder cancer and upper tract urothelial carcinoma. This study validated the risk classification for recurrence following radical cystectomy and radical nephroureterectomy using the CheckMate 274 criteria in real-world practice. Further research would help assess the degree of benefit obtained from adjuvant nivolumab.

19 February 2026 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
MKMinoru Kato
Minoru Kato
TMTaisuke Matsue
Taisuke Matsue
SYShoma Yamamoto
Shoma Yamamoto
NYNao Yukimatsu
Nao Yukimatsu
TOTaiyo Otoshi
Taiyo Otoshi
JUJunji Uchida
Junji Uchida
Cisplatin-based neoadjuvant chemotherapy (NAC) improves outcomes in muscle-invasive bladder cancer (MIBC), whereas the efficacy of carboplatin-based or suboptimal regimens remains unclear. We retrospectively reviewed 265 patients who underwent radical cystectomy, including 164 with MIBC. Among them, 21 received ≥3 cycles of gemcitabine/cisplatin (optimal NAC), 44 received ≤2 cycles of cisplatin-based NAC, 36 received gemcitabine/carboplatin (GCarb) NAC, and 63 underwent cystectomy alone. Propensity score matching was applied to compare the GCarb and no-NAC cohorts based on clinical stage, performance status, and renal function. The pathological complete response rate did not differ between the groups. Disease-free survival tended to be worse in the GCarb cohort (P = .07). Importantly, the median time-to-cystectomy from diagnosis with MIBC was significantly longer with GCarb than no-NAC cohort (3.1 vs. 1.5 months). These findings suggest that GCarb-based NAC may be detrimental by delaying surgery without providing oncological benefit, reinforcing guideline recommendations against its use in MIBC.

29 July 2026 in International Journal of Urology
Verified
Journal Article
Closed access
PDF file
NYNao Yukimatsu
Nao Yukimatsu
TYTakeshi Yamasaki
Takeshi Yamasaki
TMTaisuke Matsue
Taisuke Matsue
SYShoma Yamamoto
Shoma Yamamoto
TOTaiyo Otoshi
Taiyo Otoshi
JUJunji Uchida
Junji Uchida

24 September 2025 in Research Square
Verified
Preprint
Open access
PDF file
SYShoma Yamamoto
Shoma Yamamoto
MKMinoru Kato
Minoru Kato
TMTaisuke Matsue
Taisuke Matsue
NYNao Yukimatsu
Nao Yukimatsu
YTYuji Takeyama
Yuji Takeyama
JUJunji Uchida
Junji Uchida
Objective Combination therapy with enfortumab vedotin (EV) and pembrolizumab has shown superior overall survival (OS) compared to platinum-based chemotherapy in advanced urothelial carcinoma (UC). Given the expanding landscape of first-line treatments, understanding site-specific effectiveness is vital for developing individualized strategies. Methods We conducted a retrospective analysis of 225 patients with advanced UC treated between April 2009 and August 2024. Systemic therapy efficacy was assessed in relation to metastatic site, focusing on site-specific responses. Patients were classified into three treatment periods (chemotherapy period [April 2009–June 2017; P1], pembrolizumab period [July 2017–December 2020; P2], and avelumab and EV period [January 2021–August 2024; P3]). Within each period, patients were stratified by metastatic pattern—lymph node-only, liver, or other—and OS was analyzed accordingly. Results The objective response rates for chemotherapy, pembrolizumab, avelumab, and EV were 41%, 23%, 20%, and 46%, respectively. Lymph node and pulmonary metastases exhibited favorable responses across all treatment modalities, whereas bone metastases consistently responded poorly. Notably, EV exhibited substantial activity against liver metastases. Median OS improved over successive treatment periods (P1: 14 months; P2: 16 months; P3: 26 months). However, patients with liver metastases experienced no meaningful OS improvement (P1: 9.5 months; P2: 9.2 months; P3: 8 months), with 54% of these patients not receiving EV. Conclusions Sequential therapies may offer a survival benefit in selected patients. EV plus pembrolizumab may be particularly beneficial in patients with rapidly progressive disease such as those with liver metastases, warranting further investigation in real-world settings.